Chembio Diagnostics to Report First Quarter 2022 Financial Results on May 5, 2022
Chembio Diagnostics, Inc. (CEMI) will release its financial results for Q1 2022 on May 5, 2022, after market close. A conference call will be held at 4:30 p.m. Eastern Time the same day, where management will discuss the results. Investors can participate by dialing the designated numbers or accessing the event online. Chembio specializes in developing point-of-care diagnostic tests for infectious diseases, including COVID-19. The company's tests are sold globally to various healthcare entities.
- None.
- None.
HAUPPAUGE, N.Y., April 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2022 after the close of trading on Thursday, May 5, 2022.
The company’s management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on May 5, 2022. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 898553 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US using passcode 45278 or by accessing www.chembio.com/investors/calendar-of-events/.
About Chembio Diagnostics
Chembio is a leading diagnostics company focused on developing and commercializing point-of-care tests used for the rapid detection and diagnosis of infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19 and other viral and bacterial infections, enabling expedited treatment. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
| Investor contact: |
| Philip Taylor Gilmartin Group (415) 937-5406 investor@chembio.com |
FAQ
When will Chembio Diagnostics release its Q1 2022 financial results?
What time is the Chembio Diagnostics conference call for Q1 2022 results?
How can I listen to the Chembio Diagnostics Q1 2022 conference call?
What is the focus of Chembio Diagnostics?
